Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases.

Benner MF, Jansen PM, Vermeer MH, Willemze R.

Blood. 2012 Feb 16;119(7):1643-9. doi: 10.1182/blood-2011-08-376319. Epub 2011 Dec 12.

2.

Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.

Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, Robson A, Calonje E, Stefanato CM, Wain EM, Wilkins B, Fields PA, Dean A, Webb K, Scarisbrick J, Morris S, Whittaker SJ.

J Clin Oncol. 2010 Nov 1;28(31):4730-9. doi: 10.1200/JCO.2009.27.7665. Epub 2010 Sep 20.

3.

Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.

Fraser-Andrews EA, Mitchell T, Ferreira S, Seed PT, Russell-Jones R, Calonje E, Whittaker SJ.

Br J Dermatol. 2006 Oct;155(4):756-62.

PMID:
16965425
4.

Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis.

Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R.

Blood. 1998 Aug 15;92(4):1150-9.

5.

Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas.

Vergier B, de Muret A, Beylot-Barry M, Vaillant L, Ekouevi D, Chene G, Carlotti A, Franck N, Dechelotte P, Souteyrand P, Courville P, Joly P, Delaunay M, Bagot M, Grange F, Fraitag S, Bosq J, Petrella T, Durlach A, De Mascarel A, Merlio JP, Wechsler J.

Blood. 2000 Apr 1;95(7):2212-8. Review.

6.

Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.

Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT.

Arch Dermatol. 2003 Jul;139(7):857-66.

PMID:
12873880
7.

Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.

Kim YH, Bishop K, Varghese A, Hoppe RT.

Arch Dermatol. 1995 Sep;131(9):1003-8.

PMID:
7661601
8.

Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sézary syndrome in the southeastern United States: a single-institution cohort.

Desai M, Liu S, Parker S.

J Am Acad Dermatol. 2015 Feb;72(2):276-85. doi: 10.1016/j.jaad.2014.10.019. Epub 2014 Nov 17.

PMID:
25458019
9.

Prognostic factor analysis in mycosis fungoides/Sézary syndrome.

Diamandidou E, Colome M, Fayad L, Duvic M, Kurzrock R.

J Am Acad Dermatol. 1999 Jun;40(6 Pt 1):914-24.

PMID:
10365922
10.

Prognostic factors in 105 Japanese cases of mycosis fungoides and Sézary syndrome: clusterin expression as a novel prognostic factor.

Tobisawa S, Honma M, Ishida-Yamamoto A, Saijo Y, Iizuka H.

J Dermatol Sci. 2013 Sep;71(3):160-6. doi: 10.1016/j.jdermsci.2013.04.020. Epub 2013 May 2.

PMID:
23702390
11.

Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome.

Suzuki SY, Ito K, Ito M, Kawai K.

J Dermatol Sci. 2010 Jan;57(1):37-43. doi: 10.1016/j.jdermsci.2009.10.010.

PMID:
19931424
12.

Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large-cell lymphoma.

Cerroni L, Rieger E, Hödl S, Kerl H.

Am J Surg Pathol. 1992 Jun;16(6):543-52.

PMID:
1599034
13.

A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.

Benton EC, Crichton S, Talpur R, Agar NS, Fields PA, Wedgeworth E, Mitchell TJ, Cox M, Ferreira S, Liu P, Robson A, Calonje E, Stefanato CM, Wilkins B, Scarisbrick J, Wain EM, Child F, Morris S, Duvic M, Whittaker SJ.

Eur J Cancer. 2013 Sep;49(13):2859-68. doi: 10.1016/j.ejca.2013.04.018. Epub 2013 Jun 1.

PMID:
23735705
14.

Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma.

Gerami P, Rosen S, Kuzel T, Boone SL, Guitart J.

Arch Dermatol. 2008 Jun;144(6):738-46. doi: 10.1001/archderm.144.6.738.

PMID:
18559762
15.

Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups.

Sausville EA, Eddy JL, Makuch RW, Fischmann AB, Schechter GP, Matthews M, Glatstein E, Ihde DC, Kaye F, Veach SR, et al.

Ann Intern Med. 1988 Sep 1;109(5):372-82.

PMID:
3408055
16.

Transformed mycosis fungoides: clinicopathological features and outcome.

Barberio E, Thomas L, Skowron F, Balme B, Dalle S.

Br J Dermatol. 2007 Aug;157(2):284-9. Epub 2007 Jun 15.

PMID:
17573879
17.

Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome. The French Study Group on Cutaneous Lymphomas.

Grange F, Hedelin G, Joly P, Beylot-Barry M, D'Incan M, Delaunay M, Vaillant L, Avril MF, Bosq J, Wechsler J, Dalac S, Grosieux C, Franck N, Esteve E, Michel C, Bodemer C, Vergier B, Laroche L, Bagot M.

Blood. 1999 Jun 1;93(11):3637-42.

18.

Recognizing large-cell transformation of mycosis fungoides.

Herrmann JL, Hughey LC.

J Am Acad Dermatol. 2012 Oct;67(4):665-72. doi: 10.1016/j.jaad.2011.12.011. Epub 2012 Jan 20.

PMID:
22261416
20.

Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients.

van Doorn R, Van Haselen CW, van Voorst Vader PC, Geerts ML, Heule F, de Rie M, Steijlen PM, Dekker SK, van Vloten WA, Willemze R.

Arch Dermatol. 2000 Apr;136(4):504-10.

PMID:
10768649
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk